These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35379801)

  • 1. EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma.
    Voeltzke K; Scharov K; Funk CM; Kahler A; Picard D; Hauffe L; Orth MF; Remke M; Esposito I; Kirchner T; Schramm A; Rotblat B; Grünewald TGP; Reifenberger G; Leprivier G
    Cell Death Discov; 2022 Apr; 8(1):157. PubMed ID: 35379801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eukaryotic translation initiation factor 4E binding protein 1 (EIF4EBP1) expression in glioblastoma is driven by ETS1- and MYBL2-dependent transcriptional activation.
    Hauffe L; Picard D; Musa J; Remke M; Grünewald TGP; Rotblat B; Reifenberger G; Leprivier G
    Cell Death Discov; 2022 Feb; 8(1):91. PubMed ID: 35228525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
    Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
    Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of OCT4 binding at the
    Nakatani K; Kogashi H; Miyamoto T; Setoguchi T; Sakuma T; Kugou K; Hasegawa Y; Yamamoto T; Hippo Y; Suenaga Y
    Front Oncol; 2024; 14():1237378. PubMed ID: 38390263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification.
    Geerts D; Koster J; Albert D; Koomoa DL; Feith DJ; Pegg AE; Volckmann R; Caron H; Versteeg R; Bachmann AS
    Int J Cancer; 2010 May; 126(9):2012-24. PubMed ID: 19960435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High
    Nelson ED; Benesch MG; Wu R; Ishikawa T; Takabe K
    Am J Cancer Res; 2024; 14(1):227-242. PubMed ID: 38323277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target Genes of c-MYC and MYCN with Prognostic Power in Neuroblastoma Exhibit Different Expressions during Sympathoadrenal Development.
    Yuan Y; Alzrigat M; Rodriguez-Garcia A; Wang X; Bexelius TS; Johnsen JI; Arsenian-Henriksson M; Liaño-Pons J; Bedoya-Reina OC
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
    Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
    Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
    Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
    Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low DLG2 gene expression, a link between 11q-deleted and MYCN-amplified neuroblastoma, causes forced cell cycle progression, and predicts poor patient survival.
    Keane S; Améen S; Lindlöf A; Ejeskär K
    Cell Commun Signal; 2020 Apr; 18(1):65. PubMed ID: 32312269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
    Yamaguchi Y; Takenobu H; Ohira M; Nakazawa A; Yoshida S; Akita N; Shimozato O; Iwama A; Nakagawara A; Kamijo T
    Eur J Cancer; 2014 May; 50(8):1555-65. PubMed ID: 24559687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of DDX1 and NAG gene amplification/overexpression to the prognosis of patients with MYCN-amplified neuroblastoma.
    Kaneko S; Ohira M; Nakamura Y; Isogai E; Nakagawara A; Kaneko M
    J Cancer Res Clin Oncol; 2007 Mar; 133(3):185-92. PubMed ID: 17028906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma.
    Manohar CF; Salwen HR; Brodeur GM; Cohn SL
    Genes Chromosomes Cancer; 1995 Nov; 14(3):196-203. PubMed ID: 8589036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of surgical radicality on outcome in childhood neuroblastoma.
    von Schweinitz D; Hero B; Berthold F
    Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.